Einrichtungen, die zum Universitätsklinikum Erlangen gehören

Identification of isoaspartate-modified transthyretin as potential target for selective immunotherapy of transthyretin amyloidosis (2024) Köppen J, Kleinschmidt M, Morawski M, Rahfeld JU, Wermann M, Cynis H, Hegenbart U, et al. Journal article Unraveling progression subtypes in people with Huntington’s disease (2024) Raschka T, Li Z, Gaßner H, Kohl Z, Jukic J, Marxreiter F, Fröhlich H Journal article Expression of Nectin-4 in Chromophobe Renal Cell Carcinoma in a Multicenter Cohort: Early Prognostic and Therapeutic Considerations (2024) Mikuteit M, Zschäbitz S, Autenrieth M, Weichert W, Hartmann A, Steffens S, Erlmeier F Journal article An Empirical Survey on the Adaption of Neoadjuvant Chemotherapy in Bladder Cancer (2024) Reike MJ, Reicherz A, Tully KH, Bahlburg H, Maas M, Bach P, Klümper N, et al. Journal article Sunitinib for Metastatic Renal Cell Carcinoma: Real-World Data from the STAR-TOR Registry and Detailed Literature Review (2024) Uhlig A, Bergmann L, Bögemann M, Fischer T, Goebell P, Leitsmann M, Reichert M, et al. Journal article Anti-PD-(L)1 plus BRAF/MEK inhibitors (triplet therapy) after failure of immune checkpoint inhibition and targeted therapy in patients with advanced melanoma. (2024) Albrecht LJ, Dimitriou F, Grover P, Hassel JC, Erdmann M, Forschner A, Johnson DB, et al. Journal article Joint recommendations on cost calculation and estimation in paediatric clinical trials (2024) Ahne G, Nagel J, Franz AR, Neubert A, Schachtrup K, Helms S, Klammt S, Schwab M Journal article, Review article Versterben im Krankenhaus – Umgang mit und Versorgung von Verstorbenen und ihren An- und Zugehörigen (2024) Kreymann F, Ahn J, Behzadi A, Sibbe A, Reinholz U, Demir M, Jentschke E, et al. Journal article Integrative multi-omics analyses to identify the genetic and functional mechanisms underlying ovarian cancer risk regions (2024) Dareng EO, Coetzee SG, Tyrer JP, Peng PC, Rosenow W, Chen S, Davis BD, et al. Journal article Quality-Assured Analysis of PIK3CA Mutations in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer Tissue: A Story About the Need for Proficiency Testing for High-Quality Molecular Biomarker Reporting in Precision Medicine (2024) Schmidt C, Stöhr R, Dimitrova L, Beckmann M, Rübner M, Fasching P, Denkert C, et al. Journal article